Physician profile
Amber Feinman
NPI 1538432232
$1,460.50
in general payments reported to CMS, 2019-2025
31 companies · $594 in 2025
The $594 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.93 · 2023: $42.31 · 2024: $810 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.58 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $195.08 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $159.95 | 2024-2025 | |
| Stemline Therapeutics INC. | $111.50 | 2023-2025 | Orserdu |
| Daiichi Sankyo INC. | $100.98 | 2024-2025 | Enhertu, Datroway |
| Seagen INC. | $99.99 | 2024 | |
| Tempus Ai, INC | $58.43 | 2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $57.83 | 2024 | Keytruda, Welireg |
| Abbvie INC. | $56.07 | 2024-2025 | |
| Janssen Biotech, INC. | $54.08 | 2024-2025 | Rybrevant, Tecvayli, Darzalex |
| Sobi, INC | $48.57 | 2024-2025 | |
| Eisai INC. | $47.78 | 2024-2025 | |
| Celgene Corporation | $40.91 | 2024 | Pomalyst |
| Astrazeneca Pharmaceuticals Lp | $36.27 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $35.41 | 2023-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $31.51 | 2024-2025 | Onivyde, Somatuline Depot |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $31.01 | 2020-2024 | Jakafi |
| Lilly USA, LLC | $30.27 | 2024-2025 | Verzenio, Jaypirca |
| Servier Pharmaceuticals LLC | $27.75 | 2024-2025 | |
| Array Biopharma INC | $27.16 | 2025 | Mektovi, Braftovi, Tukysa |
| Sandoz INC. | $25.54 | 2025 | |
| Novocure INC. | $21.35 | 2025 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.40 | 2024 | |
| Janssen Pharmaceuticals, INC | $19.24 | 2024 | Xarelto |
| Emd Serono, INC. | $17.40 | 2025 | |
| Taiho Oncology, INC. | $17.22 | 2024 | |
| Tersera Therapeutics LLC | $16.51 | 2025 | Zoladex |
| Genentech USA, INC. | $16.49 | 2025 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $15.04 | 2024 | Ninlaro |
| Jazz Pharmaceuticals INC. | $14.57 | 2024 | |
| Exelixis INC. | $13.70 | 2025 | Cabometyx |
| Gilead Sciences, INC. | $13.49 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Feinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.